While porridge is often considered a healthy start, experts warn that oats may not be suitable for everyone due to concerns about mineral absorption and blood sugar spikes. A balanced breakfast with protein and fats might be a better option…
Incorporating more fibre-rich non-starchy vegetables like broccoli, leafy greens, and peppers into your diet can help maintain steadier blood sugar levels, offering a simple strategy for metabolic health. Eating more non-starchy vegetables may help people keep blood sugar on a…
Researchers in China have developed a ginger-derived nanoparticle system that delivers a DNAzyme targeting VEGFA mRNA, potentially paving the way for earlier and less invasive treatments for diabetic retinopathy. Researchers in China have reported a ginger-derived nanoparticle system that may…
Retatrutide, a novel triple-action hormone drug, shows promising results in weight loss and diabetes management, signalling a shift towards more aggressive obesity therapies pending regulatory approval. Retatrutide has emerged as one of the most closely watched experimental obesity medicines because…
Experimental drug retatrutide, a triple-action obesity treatment showing promising weight and blood-sugar control, faces safety concerns and illegal market activity as it remains investigational. Retatrutide has emerged as one of the most talked-about experimental obesity medicines, with the Foodmakers report…
Eli Lilly’s novel combination of amylin drug eloralintide with tirzepatide shows significant weight loss and improved blood sugar control in phase 2 trials, posing a challenge to competitors despite concerns over side effects. Eli Lilly has once again widened its…
Eli Lilly advances its obesity treatment pipeline with promising Phase 2b results for a novel drug combo that surpasses existing therapies in weight loss and metabolic improvements, setting the stage for future Phase 3 trials. Eli Lilly has strengthened its…
Boehringer Ingelheim’s experimental weekly injection, survodutide, demonstrates significant weight loss and better blood sugar control in a phase 3 trial, offering a potential new approach to tackling obesity and diabetes, though concerns around tolerability remain. An experimental weekly injection from…
Eli Lilly’s experimental once-daily pill Foundayo, also known as orforglipron, demonstrates comparable heart safety to insulin glargine and superior glucose control, marking a potential breakthrough in oral diabetes treatments amid safety and tolerability considerations. Eli Lilly said its once-daily pill…
A phase 3 trial reveals that survodutide, an experimental injection, can significantly reduce weight and improve blood sugar levels in adults with obesity or type 2 diabetes, though side effects may limit its use. An experimental weekly injection called survodutide…
